SCHEMBL5759934

SCHEMBL5759934

Cc1ccc(F)cc1CNS(=O)(=O)c1ccc(Cc2ccc3oc(=O)cc(C(F)(F)F)c3c2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
KDM4E B2RXH2 3/20 0.41
GLA P06280 1/20 0.41
POLB P06746 1/20 0.41
GAA P10253 1/20 0.41
PKM P14618 1/20 0.41
ERAP1 Q9NZ08 1/20 0.41
AR P10275 4/20 0.39
CA9 Q16790 2/20 0.38
CA12 O43570 1/20 0.38
CYP1A2 P05177 2/20 0.37
CYP1A1 P04798 1/20 0.37
CYP1B1 Q16678 1/20 0.37
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
HPGD P15428 3/20 0.35
LMNA P02545 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5760027 0.89 ALDH1A1 (0.37) ALDH1A1KDM4EGLAPOLBGAA
SCHEMBL5761672 0.89 MEN1 (0.47) ALDH1A1KDM4EGLAPOLBGAA
SCHEMBL5761054 0.88 CA1 (0.46) ALDH1A1KDM4EGLAPOLBGAA
SCHEMBL5861070 0.88 AR (0.39) ALDH1A1KDM4EGLAPOLBGAA
SCHEMBL5762259 0.85 ALDH1A1 (0.49) ALDH1A1KDM4EGAAARCA9
SCHEMBL5762510 0.84 NAMPT (0.44) ALDH1A1KDM4EGAAARCYP1A2
SCHEMBL5762290 0.84 CYP19A1 (0.41) ARCA9CYP1A2CYP1A1CYP1B1
SCHEMBL5759734 0.83 AR (0.36) ALDH1A1KDM4EGLAPOLBGAA
SCHEMBL5761760 0.83 CYP1A2 (0.41) ALDH1A1KDM4EGLAPOLBGAA
SCHEMBL5761740 0.82 AR (0.40) ARCYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7098340-B2 Quinoline/chromene derivatives as androgen antagonist WARNER LAMBERT COMPANY LLC (US) 2006-08-29 US claimed
EP-1633732-A1 BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 2006-03-15 EP claimed
US-20050137228-A1 Benzyl sulfonamide derivatives DU DANIEL Y (US) 2005-06-23 US claimed
WO-2004101544-A1 BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY LLC (US) 2004-11-25 WO claimed
US-7098340-B2 Quinoline/chromene derivatives as androgen antagonist WARNER LAMBERT COMPANY LLC (US) 2006-08-29 US disclosed
US-20050137228-A1 Benzyl sulfonamide derivatives DU DANIEL Y (US) 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137228-A1 Benzyl sulfonamide derivatives AR, SHBG, BRDT ALDH1A1 1928/4885KDM4E 870/4885GLA 2343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.